2. Dodiuk-Gad RP, Olteanu C, Feinstein A, et al. Major psychological complications and
decreased health-related quality of life among survivors of Stevens-Johnson syndrome and …

Background: Secukinumab is an anti-IL-17A monoclonal antibody approved for the
treatment of moderate-to-severe psoriasis in adult patients. Despite its favourable safety and …

Background Secukinumab is administered at the labelled dose of 300 mg at weeks 0, 1, 2, 3,
4 (loading dose) and every 4 weeks thereafter. Objectives To investigate the efficacy of …

Secukinumab Retreatment Shows Rapid Recapture of Treatment Response: an Analysis of a
Phase 3 Extension Trial in Psoriasis 4879 Page 1 Secukinumab Retreatment Shows Rapid …

This study assessed the effectiveness and safety of secukinumab in patients with moderate‐
severe psoriasis vulgaris in a real‐world setting. A total of 120 patients (35.8% women; …

Background Few studies have investigated the long‐term outcomes of secukinumab in real‐
life psoriasis treatment where diverse patient profiles require a personalized approach …

Secukinumab (Cosentyx™) is a human monoclonal IgG1k antibody that has been
developed to target and block the actions of IL-17A. It is known that this cytokine is elevated …

Abstract Secukinumab (anti‐IL17A) is effective as treatment for moderate to severe plaque
psoriasis, but real‐life data on effectiveness and safety lack. We aimed to present real‐life …

Objective To describe real-world baseline characteristics and patient-reported outcomes
(PROs) at 6-month and 12-month follow-up visits among patients with psoriasis who initiated …

Background Psoriasis is associated with metabolic, liver and cardiovascular comorbidity.
Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin …